SG11202008612XA - Combination of anti-hgfr antibody and hegfr for the treatment of a tumor and/or metastasis - Google Patents

Combination of anti-hgfr antibody and hegfr for the treatment of a tumor and/or metastasis

Info

Publication number
SG11202008612XA
SG11202008612XA SG11202008612XA SG11202008612XA SG11202008612XA SG 11202008612X A SG11202008612X A SG 11202008612XA SG 11202008612X A SG11202008612X A SG 11202008612XA SG 11202008612X A SG11202008612X A SG 11202008612XA SG 11202008612X A SG11202008612X A SG 11202008612XA
Authority
SG
Singapore
Prior art keywords
hegfr
metastasis
tumor
treatment
combination
Prior art date
Application number
SG11202008612XA
Other languages
English (en)
Inventor
Cristina Basilico
Elisa Vigna
Paolo Maria Comoglio
Original Assignee
Metis Prec Medicine Sb S R L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metis Prec Medicine Sb S R L filed Critical Metis Prec Medicine Sb S R L
Publication of SG11202008612XA publication Critical patent/SG11202008612XA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • Communicable Diseases (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG11202008612XA 2018-03-22 2019-03-21 Combination of anti-hgfr antibody and hegfr for the treatment of a tumor and/or metastasis SG11202008612XA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT102018000003875A IT201800003875A1 (it) 2018-03-22 2018-03-22 Nuova combinazione di agenti terapeutici per il trattamento di un tumore e/o metastasi
PCT/IB2019/052307 WO2019180658A1 (en) 2018-03-22 2019-03-21 Combination of anti-hgfr antibody and hegfr for the treatment of a tumor and/or metastasis

Publications (1)

Publication Number Publication Date
SG11202008612XA true SG11202008612XA (en) 2020-10-29

Family

ID=62530500

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202008612XA SG11202008612XA (en) 2018-03-22 2019-03-21 Combination of anti-hgfr antibody and hegfr for the treatment of a tumor and/or metastasis

Country Status (13)

Country Link
US (1) US11814433B2 (https=)
EP (1) EP3768710A1 (https=)
JP (1) JP7381555B2 (https=)
KR (1) KR20200135449A (https=)
CN (1) CN112041340A (https=)
AU (1) AU2019240274B2 (https=)
BR (1) BR112020018981A8 (https=)
CA (1) CA3093513A1 (https=)
IL (1) IL277476B1 (https=)
IT (1) IT201800003875A1 (https=)
MX (1) MX2020009787A (https=)
SG (1) SG11202008612XA (https=)
WO (1) WO2019180658A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3413363B1 (en) * 2016-02-02 2021-03-24 National Institute for Materials Science Ferromagnetic tunnel junction, magnetoresistive effect element and spintronics device in which said ferromagnetic tunnel junction is used, and method of manufacturing ferromagnetic tunnel junction
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof
WO2025188676A1 (en) * 2024-03-04 2025-09-12 The Board Of Trustees Of The Leland Stanford Junior University Genetic engineering of cells for secretion of therapeutic antibodies

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1959955T3 (pl) * 2005-12-05 2011-04-29 Pfizer Prod Inc Sposób traktowania nieprawidłowego wzrostu komórek
ES2368864T3 (es) * 2006-02-06 2011-11-23 Metheresis Translational Research Sa Anticuerpos monoclonales anti-met, sus fragmentos y vectores para el tratamiento de tumores y productos correspondientes.
CN101914161B (zh) * 2010-08-13 2013-12-11 四川大学 抑制肿瘤生长的融合蛋白HGFα-Fc及其用途
ITTO20130012A1 (it) * 2013-01-09 2014-07-10 Metheresis Translational Res S A Nuovi frammenti anticorpali, relative composizioni ed usi

Also Published As

Publication number Publication date
EP3768710A1 (en) 2021-01-27
IT201800003875A1 (it) 2019-09-22
IL277476A (en) 2020-11-30
BR112020018981A2 (pt) 2021-01-05
IL277476B1 (en) 2026-01-01
WO2019180658A1 (en) 2019-09-26
MX2020009787A (es) 2020-11-09
CN112041340A (zh) 2020-12-04
CA3093513A1 (en) 2019-09-26
BR112020018981A8 (pt) 2022-06-28
US20210070868A1 (en) 2021-03-11
RU2020129465A (ru) 2022-04-22
JP7381555B2 (ja) 2023-11-15
AU2019240274A1 (en) 2020-10-15
JP2021518170A (ja) 2021-08-02
KR20200135449A (ko) 2020-12-02
AU2019240274B2 (en) 2025-04-24
US11814433B2 (en) 2023-11-14

Similar Documents

Publication Publication Date Title
IL289650A (en) Azolopyrimidine for the treatment of cancer-related disorders
IL264674B1 (en) Antibodies to siglec7 for cancer treatment
IL275737A (en) Variant antibodies against TIGIT
IL275482A (en) Asketamine for the treatment of depression
IL273402A (en) Antibodies against human leukocyte antigens type A2 and methods of using them
EP3793523B8 (en) Formulations and methods for the prevention and treatment of tumor metastasis and tumorigenesis
IL283948A (en) Methods for treating depression
GB201820450D0 (en) Compound and its use for the treatment of alpha1-antitryspin deficiency
ZA201806469B (en) Neural thread peptide for preventing or reducing the progression of prostate cancer
ZA201807132B (en) Humanized anti-basigin antibodies and the use thereof
IL282007A (en) Medicine to treat chronic cough
IL271934A (en) Methods for treating tumor metastases
IL277007A (en) Therapeutic ANTI-SPLA2-GIB antibodies and their uses
IL277476A (en) A combination of anti-hepatocyte growth hormone receptor antibody and human epidermal hepatocyte growth hormone receptor for the treatment of cancerous tumor and/or metastasis
LT3377064T (lt) Orvepitantas, skirtas lėtinio kosulio gydymui
IL280468A (en) Secondary vaccine particles for cancer treatment
PL3630754T3 (pl) Związki izoindolinoacetylenowe do leczenia nowotworu
ZA201806320B (en) Sultiame for the treatment of sleep apnea
SG11202103575RA (en) Anti-met fab-fc for the treatment of a tumor and/or metastasis
SG11202012771UA (en) Treatment of residual streams from the manufacture of bisphenols
IL277902A (en) Nazartinib for use in the treatment of CNS metastasis
HK40036190A (en) Nazartinib for use in the treatment of cns metastasis
GB201820455D0 (en) Compounds and their use for the treatment of alpha1-antitryspin deficiency
GB201820452D0 (en) Compounds and their use for the treatment of alpha1-antitryspin deficiency
HK40023959A (en) Methods of treating tumor metastasis